63- Trastuzumab, ramucirumab, apatinib, and nivolumab are the
only target therapies that have proven statistical; if not really,
clinical, significant improvement in survival outcomes in phase
III randomized controlled trials. In addition, the results of
some of the target agents were only positive in certain sub-
groups of patients. - Gastric and esophagogastric junction adenocarcinoma are gen-
uinely highly heterogeneous and a more personalized strategy
should be adopted.
References
- Wagner AD, Unverzagt S, Grothe W (2010)
Chemotherapy for advanced gastric cancer.
Cochrane Database Syst Rev 17:CD004064 - Cunningham D, Starling N, Rao S et al (2008)
Capecitabine and oxaliplatin for advanced esoph-
agogastric cancer. N Engl J Med 358:36–46 - Koizumi W, Narahara H, Hara T et al (2008)
S-1 plus cisplatin versus S-1 alone for first-line
treatment of advanced gastric cancer (SPIRITS
trial): a phase III trial. Lancet Oncol 9:215–221 - Van Cutsem E, Moiseyenko VM, Tjulandin S
et al (2006) Phase III study of docetaxel and
cisplatin plus fluorouracil compared with cis-
platin and fluorouracil as first-line therapy for
advanced gastric cancer: a report of the V325
Study Group. J Clin Oncol 24:4991–4997 - McCormick Matthews LH, Noble F, Tod
J et al (2015) Systematic review and meta-
analysis of immunohistochemical prognostic
biomarkers in resected esophageal adenocarci-
noma. Br J Cancer 113:107–118. https://doi.
org/10.1038/bjc.2015.179 - The Cancer Genome Atlas Research Network
(2017) Integrated genomic characterization of
esophageal carcinoma. Nature 541:169–175 - Gravalos C, Jimeno A (2008) HER2 in gas-
tric cancer: a new prognostic factor and a novel
therapeutic target. Ann Oncol 19:1523–1529 - Bang YJ, Van Cutsem E, Feyereislova A et al
(2010) Trastuzumab in combination with
chemotherapy versus chemotherapy alone for
treatment of HER2-positive advanced gastric
or gastro-esophageal junction cancer (ToGA):
a phase 3, open-label, randomised controlled
trial. Lancet 376:687–697 - Hecht JR, Bang YJ, Qin SK et al (2016)
Lapatinib in combination with capecitabine
plus oxaliplatin in HER2-positive advanced or
metastatic gastric, esophageal, or gastresopha-
geal adenocarcinoma: (TRIO- 013/LOGiC)
a randomized phase III trial. J Clin Oncol
34:443–451
10. Swain SM, Baselga J, Kim SB et al (2015)
Pertuzumab, trastuzumab, and docetaxel in
HER2-positive metastatic breast cancer. N
Engl J Med 372:724–734
11. Shitara K, Yatabe Y, Matsuo K et al (2013)
Prognosis of patients with advanced gastric
cancer by HER2 status and trastuzumab treat-
ment. Gastric Cancer 16:261–267
12. Li Q, Jiang H, Li H et al (2016) Efficacy of
trastuzumab beyond progression in HER2
positive advanced gastric cancer: a multi-
center prospective observational cohort study.
Oncotarget 7:50656–50665
13. Al-Shamsi HO, Fahmawi Y, Dahbour I et al
(2016) Continuation of trastuzumab beyond
disease progression in HER2-positive meta-
static gastric cancer: the MD Anderson experi-
ence. J Gastrointest Oncol 7:499–505
14. Satoh T, Xu RH, Chung HC et al (2014)
Lapatinib plus paclitaxel versus paclitaxel
alone in the second-line treatment of HER2-
amplified advanced gastric cancer in Asian
populations: TyTAN—a randomized, phase III
study. J Clin Oncol 32:2039–2049
15. Lewis Phillips GD, Li G, Dugger DL et al
(2008) Targeting HER2-positive breast cancer
with trastuzumab-DM1, an antibody-cytotoxic
drug conjugate. Cancer Res 68:9280–9290
16. Verma S, Miles D, Gianni L et al (2012)
Trastuzumab emtansine for HER2-positive
advanced breast cancer. N Engl J Med
367:1783–1791
17. Krop IE, Kim S, González-Martín A et al
(2014) Trastuzumab emtansine versus treat-
ment of physician’s choice for pretreated
HER2- positive advanced breast cancer
(TH3RESA): a randomised, open-label, phase
3 trial. Lancet Oncol 15:689–699
18. Thuss-Patience PC, Shah MA, Ohtsu A et al
(2017) Trastuzumab emtansine versus tax-
ane use for previously treated HER2-positive
locally advanced or metastatic gastric or
Target Therapy of Esophageal Adenocarcinoma